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Abstract We have identified the multiple PDZ domain contain-
ing protein (MUPP-1 or MPDZ) as a novel binding partner of
the human c-Kit. c-Kit binds specifically to the 10th PDZ domain
of MUPP-1 via its C-terminal sequence. Furthermore, a kinase
negative-mutant receptor interacted more strongly with MUPP-
1 than the wild-type c-Kit. Strikingly, a constitutively activated
c-Kit (D816V-Kit) did not bind to MUPP-1, although this
oncogenic form retains the PDZ binding motif ‘HDDV’ at the
C-terminal end. Deletion of V967 of c-Kit abolished binding to
MUPP-1 and drastically reduced its tyrosine kinase activity,
suggesting that the structure of the C-terminal tail of c-Kit
influences its enzymatic activity. ß 2000 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
The c-kit protooncogene encodes the receptor for the stem
cell factor (SCF). Interactions between c-Kit and its ligand
induces di¡erentiation, proliferation, survival, and/or secre-
tion of mediators in several cell lineages including mast cells,
melanocytes, hematopoietic stem cells, intraepithelial lympho-
cytes, interstitial cells of Cajal and germ cells [1].
The human c-Kit contains a cytoplasmic tyrosine kinase
domain which is split into two subdomains, designated K1
and K2, by an insertion of approximately 76 amino acids,
termed the kinase insert (KI) region. Furthermore, a segment
of 36 amino acids, termed the juxtamembrane (JX) domain,
separates the membrane spanning domain from the ¢rst tyro-
sine kinase (K1) domain. The C-terminal domain (CT) con-
tains about 67 amino acids and proceeds the K2 domain.
Interestingly, the amino acid sequence at the C-terminus is
‘HDDV’ which may provide a binding site for group II
PDZ domains [2]. It has been demonstrated that the human
c-kit cell line (HMC-1), established from peripheral blood of
a patient with mast-cell leukemia [3], or cells from mastocy-
tosis with an associated hematologic disorder [4] exhibit point
mutations in the cytoplasmic domain of c-Kit (D816V muta-
tion), which promote ligand independent autophosphorylation
of the mutant receptor [5]. Activation of the tyrosine kinase
leads to autophosphorylation of the cytoplasmic domain of
the receptor at multiple sites. The newly formed phosphotyro-
sine residues constitute binding sites for src homology (SH)2
domain-containing cytoplasmic proteins which may partici-
pate in the control of mitogenic pathways, cell di¡erentiation,
cell metabolism, or cell morphology.
In addition to SH2 domains, several interacting domains
for the assembly of signaling complexes have been reported
[6]. One of them, the PDZ domain, was ¢rst noted as repeated
sequences in the brain-speci¢c protein PSD-95, the Drosophila
septate junction protein Disc-large, and the epithelial tight-
junction protein ZO-1 [7,8]. PSD-95 interacts with cytoplas-
mic tail sequences of ion channel subunits, including the NR2
subunits of the NMDA receptor [9] and Shaker-type K
channel [10]. Recently, the C-terminus of AMPA receptors
was shown to interact with one of the PDZ domains of
GRIP [11]. Furthermore, the concept of receptor C-terminal
interaction with PDZ domains also extends to G-protein
coupled receptors [12,13], or members of the tyrosine kinase
receptor family, including Eph [14,15] and ErbB-4 [16].
In this paper, we describe the cloning of a cDNA encoding
a novel binding protein to c-Kit, the multiple PDZ domain
containing protein (MUPP-1, or MPDZ) [13,17], by yeast
two-hybrid screening using the cytoplasmic domain of c-Kit.
This protein associated more strongly with the kinase negative
c-Kit (K623M-c-Kit) than the wild-type (wt) c-Kit. Further-
more, an oncogenic c-Kit (D816V-c-Kit) did not bind to this
protein, suggesting that the tertiary structure of the C-termi-
nal end of c-Kit is important for its tyrosine kinase activity
and that MUPP-1 may play a role for regulation of c-Kit
tyrosine kinase activity.
2. Materials and methods
2.1. Plasmid constructions and yeast two-hybrid screening
For expression of the cytoplasmic domains of wt and mutant c-Kit
as LexA-fusions, corresponding fusion genes were generated in
pBTM116 and transformed into yeast strain L40 or YRN974
[18,19]. A single colony, selected for expression of the LexA^c-Kit
fusion-protein, was tested for c-Kit autophosphorylation and used
for transformation together with a VP16 cDNA library derived
from a 10^11-day mouse embryo [19^21]. GST^c-Kit and GST^
MUPP-1 fusion proteins were generated in the pGex system (Pharma-
cia, Freiburg, Germany).
2.2. Binding assay using the two-hybrid system
The qualitative and quantitative evaluations of various two-hybrid
protein^protein interaction were described previously [18].
2.3. Cells and antibodies
TF-1 (kind gift from C. Stocking, Hamburg, Germany) and M-07e
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(from DSMZ) cells were grown in RPMI 1640 medium supplemented
with 15% FCS and human recombinant granulocyte/macrophage col-
ony stimulating factor (200 U/ml). Monoclonal antibody against
phosphotyrosine (4G10) was from Upstate Biotechnology Inc. (Lake
Placid, NY, USA), and polyclonal antibody against c-Kit was from
Santa Cruz Biotechnology (Santa Cruz, CA, USA).
2.4. Northern blotting
Northern blotting with MUPP-1-speci¢c and actin-speci¢c probes
were performed as described [22]. Mouse multiple tissue Northern
¢lters (MTN1) were purchased from Clontech Lab. Inc. (Palo Alto,
CA, USA).
2.5. Immunoblotting
Immunoblotting was performed as published [18,23]. Bound radio-
activity was quanti¢ed with a model BAS1500 bio-imaging analyzer
(Fuji Photo Film Co., Kanagawa, Japan).
2.6. In vitro transcription/translation
In vitro transcription/translation was performed using TNT-
coupled reticulocyte lysate systems (Promega, Madison, WI, USA).
2.7. GST binding assay
Puri¢ed GST fusion proteins were bound for 1 h at 4‡C to gluta-
thione (GT) agarose beads (10 Wl slurry; Pharmacia) suspended in
binding bu¡er (50 mM HEPES, pH 7.5, 150 mM NaCl, 0.01% Triton
X-100, 1% trasylol, 10% glycerol, 1 mM phenylmethylsulfonyl £uoride
and 400 WM sodium orthovanadate). Precharged beads were incu-
bated overnight at 4‡C with 35S-labeled MUPP-1(PDZ8-13) as gen-
erated by in vitro transcription/translation in a total volume of 2 ml of
binding bu¡er. Beads were washed ¢ve times with binding bu¡er and
pellets were analyzed by SDS^PAGE.
3. Results and discussion
3.1. Isolation of MUPP-1 as binding protein of human c-Kit by
yeast two-hybrid screening
We used a yeast two-hybrid screen to ¢nd speci¢c binding
proteins of the c-Kit tyrosine kinase. The cytoplasmic domain
of c-Kit was expressed as a LexA-fusion protein. It should be
noted that the LexA-domain induces dimerization of the fu-
sion protein and thus causes activation of the tyrosine kinase
[21]. We analyzed 200 clones and 90 of these encoded the SH2
domain of the p85 subunit of the PI-3P-kinase. Furthermore,
105 cDNA clones encoded the 10th PDZ domain of mouse
MUPP-1 [13]. The Rat MUPP-1 cDNA was cloned previously
from a brain cDNA library by yeast two-hybrid screening
using serotonin receptor 2C as a bait [13]. To obtain the
full length mouse cDNA we screened mouse spleen and brain
libraries. Surprisingly, the MUPP-1 derived from the mouse
brain cDNA library (Stratagene, La Jolla, CA, USA) lacked
114 amino acids (431^543) within the third to fourth PDZ
domains, in comparison to the published sequence derived
from mouse (AJ131869), rat (AJ001380) and human
(AF093419). Furthermore, the MUPP-1 from the mouse
spleen cDNA library (Stratagene) lacked 71 amino acids con-
taining part of the seventh PDZ domain (Fig. 1A). Taken
together, MUPP-1 transcripts may be expressed as multiple-
spliced forms. We therefore next studied the tissue speci¢c
expression of the MUPP-1 gene using probes derived from
Fig. 1. Expression pattern of MUPP-1. A: Segmentation of the MUPP-1. Splice variants obtained from the spleen and brain cDNA libraries.
1^3: cDNA fragments detected by yeast two-hybrid screening of a murine embryo (11 days) cDNA library. B,C: Northern blot analyses of
MUPP-1: 32P-radiolabeled 5P (74^2083) and 3P (4700^4980) of MUPP-1 probes were hybridized to mouse MTN1 ¢lter, Clontech Lab. Inc,
Palo Alto, USA). B: 1 day exposure. C: 3 days exposure.
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5P (nucleotide number 74^2083) or 3P (4700^4980) (numbers
are according to the cDNA sequence published in Simpson et
al. [17]). As shown in Fig. 1B, the expression level of MUPP-1
was rather weak, but the 8.5 kb MUPP-1 mRNA could be
detected in all tissues after longer exposures (Fig. 1C). In
short exposures, an 8.5 kb transcript was detected in tissues
such as heart, skeletal muscle and testis using both 5P and 3P
probes (Fig. 1B). In addition, we detected three additional
transcripts of 7.5, 5.0 and 1 kb. Both the 7.5 kb and 5.0 kb
mRNAs were only detectable using a 3P probe. The 7.5 kb
and 5.0 kb mRNAs were most predominant in skeletal muscle
and liver, respectively. The 1.0 kb mRNA was only detectable,
however, with the 5P probe. At the moment we do not know
whether these transcripts are derived from di¡erent genes or
splice variants. In agreement with these data, Ullmer et al. [13]
have also shown 8.5 and 5.0 kb mRNAs by Northern blot
using a 3P probe. Interestingly, another PDZ domain contain-
ing protein, PDZ-73, which contains three PDZ domains, has
at least ¢ve di¡erent tissue-speci¢c splice variants, encoding
73, 59, 54, 45, and 37 kDa proteins [24]. The biological sig-
ni¢cance of multiple transcripts of MUPP-1 remains to be
studied.
3.2. Human c-Kit binds to MUPP-1 via the C-terminal end
In most of cases, PDZ domains interact with cytoplasmic
tail sequences of proteins [9^15]. Analysis of the amino acid
sequence of the C-terminus of human c-Kit revealed ‘-HDDV-
COOH’ the consensus sequence of the group II PDZ domain
binding site [2]. To test whether the V976 of human c-Kit is
required for this interaction, we generated a deletion mutant
lacking V976 (v976-Kit). The cytoplasmic domain of the
v976-Kit mutant was fused to LexA and the interaction
with VP16-MUPP-1 by the yeast two-hybrid system was mea-
sured. To achieve better quanti¢cation of this interaction, we
modi¢ed a currently available screening system [20] and gen-
erated a yeast strain, YRN974, in which the reporter gene,
encoding the green £uorescent protein (GFP), was chromoso-
mally integrated downstream of a LexA binding site
[18,19,25]. Activation of GFP was quanti¢ed by £ow cytomet-
ric analyses. As expected, the v976-Kit mutant failed to inter-
act with MUPP-1 (Fig. 2B). To our surprise, however, this
mutant lost its kinase activity in yeast (data not shown), and
failed even to interact with the PI-3P-kinase (Fig. 2B). To
further con¢rm the importance of the last V of c-Kit for
this interaction, we generated GST fusion proteins containing
the last 90 amino acids of the human wt-c-Kit (c-Kit (877^
976)) and the v976 c-Kit (c-Kit(877^975)). As shown in Fig.
2C, GST^wt c-Kit interacted with in vitro 35S-labeled last six
PDZ domain, but GST^v976 c-Kit did not associate with
MUPP-1.
3.3. The C-terminal end of c-Kit speci¢cally binds to the 10th
PDZ domain
Groups of PDZ domains have been classi¢ed by their rec-
ognition of unique C-terminal motifs [2]. Sequence ‘HDDV’ is
Fig. 2. Human c-Kit binds to MUPP-1 via the C-terminal end.
A: Protein^protein interaction measured by the yeast two-hybrid
analyses using the GFP gene as a reporter. Yeast strain YRN974
with an integrated LexA-Operator-GFP cassette was supplied for
two-hybrid interaction analyses [18]. The £ow cytometric quanti¢ca-
tion analyses of two-hybrid interactions of MUPP-1, and PI-3P-ki-
nase (PI-3PK) with c-Kit and c-Kit mutants. pBTM116 carrying
cDNAs which encode wt-c-Kit and the last V deletion mutant
(v976-Kit) were transformed with either pVP16 vector alone (VP16),
pVp16 carrying cDNAs encoding the 10th PDZ domain of MUPP-1
or the SH2 domains of the p85 subunit of PI-3PK. For each assay,
standard deviations were calculated from four independent experi-
ments. 10 000 cells of four independent transformants were analyzed
for £uorescence intensity using a Becton Dickinson FACScan £ow
cytometer. B: GST fusion proteins containing the last 90 amino
acids of the human c-Kit (c-Kit (877^976)) and the last V deletion
mutant (v976-Kit) were incubated overnight at 4‡C with 35S-labeled
MUPP-1, as generated by in vitro transcription/translation (Prome-
ga). Binding materials were analyzed by SDS^PAGE.
Fig. 3. 10th PDZ domain bound to the C-terminal end of c-Kit.
GST, GST^PDZ8 (amino acid number 1334^1421), GST^PDZ9
(amino acid number 1467^1552), GST^PDZ10 (amino acid number
1570^1700), GST^PDZ11/12 (amino acid number 1706^1792), GST^
PDZ12 (amino acid number 1843^1933), and GST^PDZ13 (amino
acid number 1962^2054) were isolated from DH5K and were incu-
bated overnight at 4‡C with M-07e cell lysates. Beads were washed
¢ve times with binding bu¡er and pellets were analyzed by SDS^
PAGE. For identi¢cation of c-Kit by immunoblotting, proteins were
transferred onto Immobilon-P sheets (Millipore, Bedford, MA,
USA) by a semi-dry blotting technique. Bound antibody was visual-
ized by incubation of blots in 3 ml of 20 mM Tris^HCl, pH 7.6,
containing 137 mM NaCl and 2 WCi of 125I-labeled anti-rabbit im-
munoglobulin G (IgG, ICN). Bound radioactivity was quanti¢ed
with a model BAS1500 bio-imaging analyzer (Fuji Photo Film Co.,
Kanagawa, Japan). Protein bands, stained with Coomassie brilliant
blue, were quanti¢ed with a High Resolution Color Sharp JX-325
scanner.
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recognized by the second group of PDZ domains, however,
the 10th PDZ domain of MUPP-1 also binds to the low af-
¢nity receptor for the nerve growth factor, p75, (data not
shown) whose C-terminal sequence is ‘TSPV’. This motif, ‘S/
TxV’, is recognized by the ¢rst group of PDZ domains. This
fact raises the question of whether or not c-Kit binds specif-
ically to a particular PDZ domain. Therefore, we tested the
interaction of c-Kit with GST^PDZ8, GST^PDZ9, GST^
PDZ10, GST^PDZ11/12, GST^PDZ12, and GST^PDZ13.
As shown in Fig. 3, only GST^PDZ10 speci¢cally bound to
c-Kit.
3.4. Kinase negative c-Kit bound to MUPP-1 but not with
oncogenic c-Kit
To see whether the binding of MUPP-1 and c-Kit correlates
with tyrosine kinase activity, we generated two kit mutants:
the kinase negative mutant (K623M) and the constitutively
active oncogenic-form of c-Kit (c-KitD816V). As shown in
Fig. 4, the kinase negative mutant bound more strongly
than the wt c-Kit. In addition, the oncogenic mutant
(D816V) failed to bind to MUPP-1. The oncogenic mutant,
however, bound to the SH2 domain of PI-3P-kinase to a sim-
ilar extent as the wt c-Kit and also associated with the SH2
domain of Grb10. In this assay system, Grb10 did not interact
with the wt c-Kit (Fig. 3), indicating that the oncogenic c-
KitD816V is more active than wt c-Kit in our yeast assay
system. Indeed, phosphotyrosine speci¢c immunoblot analyses
revealed that oncogenic D816V mutant was phosphorylated
about 20 fold more than wt c-Kit in yeast cells (data not
shown). In agreement with these data, Yokouchi et al. [26]
reported that oncogenic D816V mutant was highly active in
yeast cells. Taken together, MUPP-1 may form a complex
with c-Kit before stimulation with SCF, but is released from
this complex after hyperactivation of the c-Kit tyrosine ki-
nase.
We show here that c-Kit associates with the 10th PDZ
domain of MUPP-1 via its C-terminal tail. This interaction
was shown by yeast two-hybrid assay and in vitro interaction
study of c-Kit using GST^PDZ fusion proteins. Furthermore,
we demonstrated that the binding of PDZ domain of MUPP-
1 to the c-Kit is dependent on the catalytic activity of the
receptor. The oncogenic D816V-c-Kit was not able to interact
with MUPP-1, and wt c-Kit bound to MUPP-1 to a lesser
extent than kinase negative c-Kit. This is the ¢rst evidence
demonstrating that the C-terminal structure of oncogenic c-
Kit is di¡erent from that of wt c-Kit. Interestingly, a single
deletion of ‘V’ at the C-terminal end abolished the kinase
activity, suggesting again that the structure of the C-terminal
tail plays a key role in regulating c-Kit kinase activity. In this
context, the viral oncogene product of Hardy-Zuckerman-4
strain of feline sarcoma virus, v-Kit, also has an altered C-
terminal end [27]. Furthermore, this portion of the receptor
acts as negative regulator of tyrosine kinase in many other
receptor tyrosine kinases, including c-Fms and epidermal
growth factor receptor [28^30]. For example, the replacement
of a tyrosine residue at the C-terminal end of c-Fms with
phenylalanine activates the Fms tyrosine kinase [28]. This ty-
rosine residue, however, is not phosphorylated, but rather the
mutation modi¢es the tertiary structure of the CT of c-Fms.
It is generally accepted that PDZ domains play a role in
protein clustering, so that signaling is triggered in a most
e⁄cient way. MUPP-1 may support signaling molecules ex-
pressed at very low levels for e⁄cient participation of signal-
ing cascades induced by SCF. Interestingly, MUPP-1 was iso-
lated as a binding protein for the G protein-coupled receptor
5-HT2c [13]. MUPP-1 may be a connector between G-coupled
receptor- and receptor tyrosine kinase-mediated signal trans-
duction pathways.
Acknowledgements: We thank R. Wilms and K. Heidrich for technical
help and C. Stocking for critically reading the manuscript. The re-
search was supported by the Deutsche Forschungsgemeinschaft (Ta-
111/7/-1 and 2), and HiLF-Program MHH to A.M.
References
[1] Ashman, L.K. (1999) Int. J. Biochem. Cell. Biol. 31, 1037^
1051.
[2] Songyang, Z., Fanning, A.S., Fu, C., Xu, J., Marfatia, S.M.,
Chishti, A.H., Crompton, A., Chan, A.C., Anderson, J.M. and
Cantley, L.C. (1997) Science 275, 73^77.
[3] Kanakura, Y., Furitsu, T., Tsujimura, T., Butter¢eld, J.H., Ash-
man, L.K., Ikeda, H., Kitayama, H., Kanayama, Y., Matsuzawa,
Y. and Kitamura, Y. (1994) Leukemia 8, 18^22.
[4] Nagata, H., Worobec, A.S., Oh, C.K., Chowdhury, B.A., Tan-
nenbaum, S., Suzuki, Y. and Metcalfe, D.D. (1995) Proc. Natl.
Acad. Sci. USA 92, 10560^10564.
[5] Tsujimura, T., Hashimoto, K., Kitayama, H., Ikeda, H., Suga-
hara, H., Matsumura, I., Kaisho, T., Terada, N., Kitamura, Y.
and Kanakura, Y. (1999) Blood 93, 1319^1329.
[6] Pawson, T. and Scott, J.D. (1997) Science 278, 2075^2080.
[7] Cho, K.O., Hunt, C.A. and Kennedy, M.B. (1992) Neuron 9,
929^942.
[8] Gomperts, S.N. (1996) Cell 84, 659^662.
[9] Niethammer, M., Kim, E. and Sheng, M. (1996) J. Neurosci. 16,
2157^2163.
[10] Kim, E., Niethammer, M., Rothschild, A., Jan, Y.N. and Sheng,
M. (1995) Nature 378, 85^88.
[11] Dong, H., O’Brien, R.J., Fung, E.T., Lanahan, A.A., Worley,
P.F. and Huganir, R.L. (1997) Nature 386, 279^284.
[12] Brakeman, P.R., Lanahan, A.A., O’Brien, R., Roche, K., Barnes,
C.A., Huganir, R.L. and Worley, P.F. (1997) Nature 386, 284^
288.
[13] Ullmer, C., Schmuck, K., Figge, A. and Lubbert, H. (1998)
FEBS Lett. 424, 63^68.
Fig. 4. Kinase negative c-Kit associates with MUPP-1 but not with
oncogenic D816V-c-Kit. Protein^protein interaction measured by
the yeast two-hybrid analyses using the GFP gene as a reporter.
The £ow cytometric quanti¢cation analyses of two-hybrid interac-
tions of MUPP-1, PI-3P-kinase (PI-3PK) or Grb10 with c-Kit and c-
Kit mutants. pBTM116 carrying cDNAs which encode wt-c-Kit, on-
cogenic c-Kit (D816V), and kinase negative mutant K623M-c-Kit
were transformed with either pVP16 vector alone (VP16), pVp16
carrying cDNAs encoding the 10th PDZ domain of MUPP-1, or
the SH2 domains of Grb10 or of the p85 subunit of PI-3P-kinase
(PI-3PK). For each assay, standard deviations were calculated from
four independent experiments. 10 000 cells of four independent
transformants were analyzed for £uorescence intensity using a Bec-
ton Dickinson FACScan £ow cytometer.
FEBS 24146 22-9-00
A. Mancini et al./FEBS Letters 482 (2000) 54^58 57
[14] Torres, R., Firestein, B.L., Dong, H., Staudinger, J., Olson, E.N.,
Huganir, R.L., Bredt, D.S., Gale, N.W. and Yancopoulos, G.D.
(1998) Neuron 21, 1453^1463.
[15] Hock, B., Bohme, B., Karn, T., Yamamoto, T., Kaibuchi, K.,
Holtrich, U., Holland, S., Pawson, T., Rubsamen-Waigmann, H.
and Strebhardt, K. (1998) Proc. Natl. Acad. Sci. USA 95, 9779^
9784.
[16] Garcia, R.A.G., Vasudevan, K. and Buonanno, A. (2000) Proc.
Natl. Acad. Sci. USA 97, 3597^3601.
[17] Simpson, E.H., Su¡olk, R. and Jackson, I.J. (1999) Genomics 59,
102^104.
[18] Mancini, A., Niedenthal, R., Joos, H., Koch, A., Trouliaris, S.,
Niemann, H. and Tamura, T. (1997) Oncogene 15, 1565^1572.
[19] Tamura, T., Mancini, A., Joos, H., Koch, A., Hakim, C., Du-
manski, J., Weidner, K.M. and Niemann, H. (1999) Oncogene
18, 6488^6495.
[20] Vojtek, A.B., Hollenberg, S.M. and Cooper, J.A. (1993) Cell 74,
205^214.
[21] Weidner, K.M., Di Cesare, S., Sachs, M., Brinkmann, V., Beh-
rens, J. and Birchmeier, W. (1996) Nature 384, 173^176.
[22] Helftenbein, G., Krusekopf, K., Just, U., Cross, M., Ostertag,
W., Niemann, H. and Tamura, T. (1996) Oncogene 12, 931^935.
[23] Joos, H., Trouliaris, S., Helftenbein, G., Niemann, H. and Ta-
mura, T. (1996) J. Biol. Chem. 271, 24476^24481.
[24] Scanlan, M.J., Williamson, B., Jungbluth, A., Stockert, E., Ar-
den, K.C., Viars, C.S., Gure, A.O., Gordan, J.D., Chen, Y.T.
and Old, L.J. (1999) Biochim. Biophys. Acta 14, 39^52.
[25] Koch, A., Mancini, A., Stefan, M., Niedenthal, R., Niemann, H.
and Tamura, T. (2000) FEBS Lett. 469, 72^76.
[26] Yokouchi, M., Suzuki, R., Masuhara, M., Komiya, S., Inoue, A.
and Yoshimura, A. (1997) Oncogene 15, 7^15.
[27] Yarden, Y., Kuang, W.J., Yang-Feng, T., Coussens, L., Mune-
mitsu, S., Dull, T.J., Chen, E., Schlessinger, J., Francke, U. and
Ullrich, A. (1987) EMBO J. 6, 3341^3351.
[28] Roussel, M.F., Shurtle¡, S.A., Downing, J.R. and Sherr, C.J.
(1990) Proc. Natl. Acad. Sci. USA 87, 6738^6742.
[29] Riedel, H., Schlessinger, J. and Ullrich, A. (1987) Science 236,
197^200.
[30] Waterman, H., Alroy, I., Strano, S., Seger, R. and Yarden, Y.
(1999) EMBO J. 18, 3348^3358.
FEBS 24146 22-9-00
A. Mancini et al./FEBS Letters 482 (2000) 54^5858
